Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lympho... ( SAN FRANCISCO Dec. 7 /- Results of th...)

Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL

Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Results of the Phase 2 clinical trial of R788 (fostamatinib disodium) in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma (NHL) will be presented today at a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting. The results affirm preliminary reports that Rigel's oral Syk inhibitor is well-tolerated by these patients and shows therapeutic benefit in patients suffering from diffuse large B-Cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Rigel will host a conference call today at 4:00 p.m. PST to discuss these results (see conference call details below).

"Despite the fact that the patients enrolled in this trial had advanced disease and had failed treatment with marketed therapies, a significant number of them were particularly responsive to Syk inhibition with R788," said Jonathan Friedberg, M.D., M.S.Sc., Associate Professor of Medicine, James P. Wilmot Cancer Center, University of Rochester and lead investigator for the clinical trial. "I am encouraged by this data and look forward to conducting additional trials of R788, particularly in patients with DLBCL and CLL/SLL types of non-Hodgkin's lymphomas," he added.

Phase 2 Results: R788 in NHL Patients - 200 mg bid

Patients Overall % Patients
NHL Type (total n=68) Response Responding
DLBCL 23 5 22%
Follicular NHL 21 2 10%
Other NHL* 24
- CLL/SLL 11 6 55%
- MCL 9 1 11%

* Other NHL patients included 11 with CLL/SLL, 9 with Mantle cell NHL, 1

GOOD

Page: 1 2 3 4
Related medicine news :

1. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
2. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
4. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health

Post Your Comments:

Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lympho...( SAN FRANCISCO Dec. 7 /- Results of th...),Health